Specify a stock or a cryptocurrency in the search bar to get a summary
Synaptogenix Inc
SNPXSynaptogenix, Inc. operates as a clinical-stage biopharmaceutical company. It is conducting clinical and preclinical studies of its lead therapeutic candidate, Bryostatin-1, in Alzheimer's disease. Its preclinical studies have also demonstrated bryostatin's regenerative mechanisms of action for the rare disease Fragile X syndrome, and for other neurodegenerative disorders, such as multiple sclerosis, stroke, and traumatic brain injury. The U.S. Food and Drug Administration has granted Orphan Drug Designation to Synaptogenix for Bryostatin-1 as a treatment for Fragile X syndrome. The company was incorporated in 2012 and is headquartered in New York, New York. Address: 1185 Avenue of the Americas, New York, NY, United States, 10036
Analytics
WallStreet Target Price
14 USDP/E ratio
0.2882Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures SNPX
Dividend Analytics SNPX
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History SNPX
Stock Valuation SNPX
Financials SNPX
Results | 2019 | Dynamics |